ABL1 and acute lymphoblastic leukemia: Using this technology, we identified very low-level ABL1 KD mutations in > 75% of patients with newly diagnosed, previously untreated Ph + ALL; however, not a single KD mutation in any patient at time of diagnosis contributed to relapse, suggesting that the majority of these pretreatment mutations are simply due to random, age-related mutagenesis.